Healthcare
Live Price
Offline$0.85
+6.25% today
1Y Change
-19.35%
Window
Jun 23, 2025 → Jun 10, 2026
Coverage: 243 bars · Jun 23, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Traws Pharma, Inc. (TRAW) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.85 and down 19.4% across the available one-year price window (Jun 23, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of +1134.5%, EPS growth of +102.4%, a dividend yield of 0.0%. What stands out right now is revenue +1134.5%, EPS +102.4%, free cash flow +30.3% with operating margin -190.1% and ROIC 1002.6%. Valuation sits in the middle of the pack at price/sales 4.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TRAW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRAW
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TRAW Max Drawdown
-65.18%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TRAW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$231.0K
+2.2% YoY
FY Net Income
-$25.2M
-55.6% YoY
Free Cash Flow
-$23.1M
-18.5% YoY
Revenue Growth
+1134.5%
EPS Growth
+102.4%
Gross Margin
100.0%
Net Margin
-141.6%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 226K | 226K | 226K | 226K | 231K |
| Gross Profit | 214K | 226K | 226K | 226K | 231K |
| Operating Income | -49M | -20M | -20M | -16M | -25M |
| EBITDA | -167M | -20M | -20M | -16M | -25M |
| Net Income | -55M | -19M | -19M | -16M | -25M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21M | 21M | 39M | 55M | 19M |
| Total Assets | 25M | 23M | 39M | 55M | 20M |
| Total Liabilities | 57M | 12M | 11M | 9M | 14M |
| Shareholder Equity | -32M | 11M | 28M | 46M | 6M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -21M | -21M | -39M | -55M | -19M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
23M
-18.4% YoY
Capital Expenditures
15K
Free Cash Flow
23M
-18.5% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-190.1%
Net Margin
-141.6%
ROE
-103.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.